We are live on ! Find out more
BNTX icon

BioNTech

287 hedge funds and large institutions have $5.9B invested in BioNTech in 2022 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 106 increasing their positions, 80 reducing their positions, and 112 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 80

0.51% less ownership

Funds ownership: 14.51% → 14.01% (-0.51%)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

15% less capital inflows, than outflows

Capital inflows: $1.25B | Capital outflows: $1.47B

19% less funds holding

Funds holding: 354 → 287 (-67)

42% less call options, than puts

Call options by funds: $534M | Put options by funds: $926M

54% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 112

Holders
287
Holders Change
-67
Holders Change %
-18.93%
% of All Funds
4.51%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
52
Increased
106
Reduced
80
Closed
112
Calls
$534​M
Puts
$926​M
Net Calls
-⁠$392​M
Net Calls Change
-⁠$45.9​M

BNTX Hedge Fund Activity: Q1 2022 in Review

287 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q1 2022, worth a combined $5.9B — down 35% from $9.07B a quarter earlier.

Sellers outnumbered buyers: 112 funds closed out of BNTX and 52 opened new positions — a net loss of 60 holders — while 80 trimmed existing stakes and 106 added.

The largest buyer was Flossbach Von Storch, opening a new position worth an estimated $323M. The largest seller was Jennison Associates, cutting an estimated $494M.

  • 287 institutional investors held BioNTech (BNTX) as of Q1 2022, down from 354 in Q4 2021.
  • Funds reported $5.9B of BioNTech stock for Q1 2022, down 35% quarter-over-quarter.
  • 52 funds opened new BioNTech positions in Q1 2022 and 112 closed out, a net change of -60 holders.
  • The largest BioNTech buyer in Q1 2022 was Flossbach Von Storch, an estimated $323M added.
  • The largest BioNTech seller in Q1 2022 was Jennison Associates, an estimated $494M sold.

Based on aggregated 13F filings for Q1 2022.